SUNWIN INTERNAT NEUTRCTL China Venture Forum: China Stocks to Watch for Monday, October 9 10/9/2006 Shanghai, China, Oct 09, 2006 (M2 PRESSWIRE via COMTEX News Network) -- China Venture Forum, a leading equity research newsletter of micro- and small-cap China Stocks, announced China Stocks to Watch for Monday, October 9, 2006 include Sunwin International Neutraceuticals, Inc. (OTC BB: SUWN) and China Technology Development Group Corporation (Nasdaq: CTDC)
China has reportedly asked local authorities to be on guard against a resurgence of bird flu with the onset of the autumn migration season.
"Autumn and winter are the prime period for bird flu outbreaks," said Yin Chengjie, vice-minister of agriculture, told the official Xinhua news agency, adding that officials "should not underestimate the difficulties in virus control."
Yin said Thursday the situation in China remained serious and warned there was still much to be done to prevent the spread of the virus, as the annual migration risked sparking new outbreaks.
On Wednesday, China's health ministry announced that a new outbreak of bird flu had killed about 1,000 poultry in northern China, the second such case in a week.
Twenty-one people in China have contracted bird flu and 14 of them have died, according to official figures. The most recent fatality occurred in July in the western region of Xinjiang.
More than 220 people have contracted the virus in Asia since the end of 2003 and 139 have died.
China confirmed in August that its first human bird flu victim died in late 2003, two years earlier than previously reported.
Sunwin International Neutraceuticals, Inc. (OTC BB: SUWN), an industry leader in the production and distribution of Chinese herbs, veterinary medicines and low calorie natural sweetener in China, announced continued increases in sales of Hypericin based products. In November 2005, Sunwin launched a marketing effort for two products employing Hypericin as a main component to deter the spread of the avian flu. Since the launch of the marketing efforts, the combined sales of both products increased from 342,300 RMB per month in November 2005 to 685,800 RMB per month in February 2006.
Hypericin is a derivative of St. Johns Wort, which is an English word for a Chinese herb manufactured by Sunwin since 1997. In recent laboratory tests, Hypericin has proven effective as a treatment for poultry infected with strands of the avian flu. The in vitro experiments, performed jointly by the South China Agricultural University and the Chinese Academy of Agricultural Sciences, indicated that when H5N1 and H9N2 avian flu viruses were treated with Hypericin at 3.72 mg/ml for 30 minutes, Hypericin was treating 100% of the viruses. Furthermore, when these viruses were treated with Hypericin at 0.744 mg/ml for 10 minutes, Hypericin was successful in treating over 99.99% of the viruses.
Sunwin coordinated on a joint project with scientists from the e Traditional Chinese Medicine department of Shangdong University, the results were two products which could suppress the spread of certain strands of the avian flu. The two products are marketed to the veterinary community in China as a food additive. The products are mixed with water to feed poultry as a preventative measure to assist in the efforts to prevent the spread of the avian flu.
In November, 2005 Sunwin announced the Department of Livestock Farming for Shandong Province Government submitted a fast-track application to the Livestock Farming Bureau of China Ministry of Agriculture for approval of Hypericin related products as a class one new veterinary medicine to treat strands of the avian flu virus. While the China Ministry of Agriculture has not provided such clearance as a class one application Sunwin can distribute as a veterinary feed additive within China.
China Technology Development Group Corporation (Nasdaq: CTDC) is engaged in providing information network security solutions and developing health food products utilizing bio-active components of bamboo in People's Republic of China.
ABOUT CHINA VENTURE FORUM
China Venture Forum ("CVF") is an independent research firm specializing in Chinese undervalued equities. Viewing China from within, we are the premier publisher of objective and independent research on Chinese micro-cap (less than $100 million market cap) and small-cap (less than $1 billion market cap) companies listed on the US stock exchanges
To receive our FREE reports as soon as they are released, please subscribe to our list at http://www.chinaventureforum.com. Our services include our daily update and coverage. Additionally we produce comprehensive research reports on these Chinese companies publicly traded on the US stock exchanges.
CVF provides its subscribers with the latest news, press releases, and research reports for all the companies highlighted on the site. CFV utilizes information believed to be reliable herein prepared all material. The information contained herein is not guaranteed by CVF to be accurate, and should not be considered to be all-inclusive. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. CFV encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and CFV makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. CFV is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. Investing in small-cap stocks is highly speculative. You should never invest in any stock mentioned in this release unless you can afford to lose your entire investment. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and CVF undertakes no obligation to update such statements.
DISCLAIMER & DISCLOSURE
CFV and its affiliates were compensated $25,000 for coverage of SUWN from a third party. CFV is not registered investment advisers or broker/dealers. CFV makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.
CONTACT: e-mail: editor@chinaventureforum.com
M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.
(C)1994-2006 M2 COMMUNICATIONS LTD
|